{"id":27507,"date":"2024-03-28T11:47:10","date_gmt":"2024-03-28T15:47:10","guid":{"rendered":"https:\/\/nephcure.org\/?page_id=27507"},"modified":"2025-12-11T15:22:48","modified_gmt":"2025-12-11T20:22:48","slug":"inhibidores-de-sglt2","status":"publish","type":"page","link":"https:\/\/nephcure.org\/es\/managing-rkd\/treatment-options\/sglt2-inhibitors\/","title":{"rendered":"Inhibidores de SGLT2"},"content":{"rendered":"
\n
Home<\/a><\/span> \/ Managing RKD<\/a><\/span> \/ Treatment Options<\/a><\/span> \/ SGLT2 Inhibitors<\/span><\/span><\/div>\n\n
\n\n

SGLT2 Inhibitors<\/h1>\n\n\n\n

Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors are a class of drug that block the kidneys from reabsorbing glucose (sugar). Instead, glucose leaves the body via urine. When blood glucose is controlled, there is less stress for the kidney. SGLT2 inhibitors are an oral medication (taken by mouth) and can help to slow the progression of kidney disease. They also help to lowering the risk of end stage kidney disease (ESKD).You may recognize them as medications that end in \u201c-flozin.\u201d Here are some examples: Farxiga (dapagliflozin), Jardiance (empagliflozin). <\/p>\n\n<\/div>\n<\/section>\n\n

\n\n
\"\"<\/figure>\n\n\n\n

How Can they Help Patients with Rare Kidney Disease (RKD)?<\/strong> <\/h2>\n\n\n\n

There are many ways SGLT2 inhibitors are thought to help in preserving kidney function. One effect of SGLT2 inhibitors is reducing blood pressure in the body and in the glomeruli (kidney filters). Reduced blood pressure in the glomeruli helps to reduce proteinuria. Spilling less protein in the urine is linked to slower progression to ESKD. SGLT2 inhibitors also protect podocytes from damage (or effacement) and loss. Podocyte loss cannot be reversed. Loss of podocytes is associated with worsening kidney function. <\/p>\n\n\n

<\/div>\n\n\n
\"\"<\/figure>\n\n\n\n

Important Note:<\/h2>\n\n\n\n

When first starting a SGLT2 inhibitor, the estimated glomerular filtration rate (eGFR) may slightly decrease. This reduction is temporary. With continued SGLT2i treatment, the \u201cdip\u201d in eGFR is typically recovered. This means, the eGFR will usually go back to the level it was when you first started taking the medication. Long term use is associated with a slower decline in eGFR (or slower progression to ESKD). (Heerspink, et. al)  <\/p>\n\n\n\n


<\/p>\n\n\n\n

*Note: The decision to prescribe a medication is the responsibility of your physician\/primary care provider based on his\/her evaluation of your condition. The above is meant for informational purposes only. Discuss this information and all information about drugs\/medications with your physician before starting or stopping any medication.<\/em><\/p>\n\n\n

\n\n
\"\"<\/figure>\n\n\n\n

Frequently Asked Questions<\/h2>\n\n\n
\n
\n\n